Home Newsfeeds Atlanta Fed’s Bostic Says More Strong Data Could Tip Fed Toward 75 Basis Point Rate Increase

Atlanta Fed’s Bostic Says More Strong Data Could Tip Fed Toward 75 Basis Point Rate Increase

-Wall Street Journal

byCharles Gross

August 25, 2022

1 minute read

-Wall Street Journal

BEN Closes $4.95M Private Placement, Appoints Paul Chang To Co-CEO; Shares Spike Higher

By Benzinga Newsdesk

May 29, 8:07 AM

Brand Engagement Network Inc. ("BEN") (NASDAQ:BNAI), an emerging provider of personalized customer engagement AI, today announced it has closed a private placement with existing investors of its common stock and warrants

BNAI

This Analyst With Over 80% Accuracy Rate Sees Around 9% Upside In Smucker – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate Analysts

By Lisa Levin

September 18, 12:20 PM

U.S. stocks closed lower on Friday, ahead of the Federal Reserve’s policy meeting this week. The Dow, meanwhile, settled slightly higher last week, while the S&P 500 and Nasdaq both recorded losses for the second straight week.

ABM

Beam Therapeutics Expects Cash, Cash Equivalents, And Marketable Securities Of $1.1B Will Enable The Company To Fund Its Anticipated Operating Expenses And Capital Expenditure Requirements At Least Into 2025

By Benzinga Newsdesk

February 28, 7:44 AM

This expectation includes funding directed toward reaching each of the key milestones for BEAM-101, BEAM-201, BEAM-301 and BEAM-302 described above, as well as continued investments in platform advancements and

BEAM

Corcept Completes Enrollment In Phase 3 Gradient Trial Of Relacorilant In Patients With Adrenal Cushing’s Syndrome

By Benzinga Newsdesk

April 1, 8:11 AM

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by

CORT

Atlanta Fed’s Bostic Says More Strong Data Could Tip Fed Toward 75 Basis Point Rate Increase

Related Posts

BEN Closes $4.95M Private Placement, Appoints Paul Chang To Co-CEO; Shares Spike Higher

This Analyst With Over 80% Accuracy Rate Sees Around 9% Upside In Smucker – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate Analysts

Beam Therapeutics Expects Cash, Cash Equivalents, And Marketable Securities Of $1.1B Will Enable The Company To Fund Its Anticipated Operating Expenses And Capital Expenditure Requirements At Least Into 2025

Corcept Completes Enrollment In Phase 3 Gradient Trial Of Relacorilant In Patients With Adrenal Cushing’s Syndrome